AMPD2 regulates GTP synthesis and is mutated in a potentially treatable neurodegenerative brainstem disorder. Akizu, N., Cantagrel, V., Schroth, J., Cai, N., Vaux, K., McCloskey, D., Naviaux, R., Van Vleet, J., Fenstermaker, A., Silhavy, J., Scheliga, J., Toyama, K., Morisaki, H., Sonmez, F., Celep, F., Oraby, A., Zaki, M., Al-Baradie, R., Faqeih, E., Saleh, M., Spencer, E., Rosti, R., Scott, E., Nickerson, E., Gabriel, S., Morisaki, T., Holmes, E., & Gleeson, J. Cell, 2013.
abstract   bibtex   
Purine biosynthesis and metabolism, conserved in all living organisms, is essential for cellular energy homeostasis and nucleic acid synthesis. The de novo synthesis of purine precursors is under tight negative feedback regulation mediated by adenosine and guanine nucleotides. We describe a distinct early-onset neurodegenerative condition resulting from mutations in the adenosine monophosphate deaminase 2 gene (AMPD2). Patients have characteristic brain imaging features of pontocerebellar hypoplasia (PCH) due to loss of brainstem and cerebellar parenchyma. We found that AMPD2 plays an evolutionary conserved role in the maintenance of cellular guanine nucleotide pools by regulating the feedback inhibition of adenosine derivatives on de novo purine synthesis. AMPD2 deficiency results in defective GTP-dependent initiation of protein translation, which can be rescued by administration of purine precursors. These data suggest AMPD2-related PCH as a potentially treatable early-onset neurodegenerative disease. © 2013 Elsevier Inc.
@article{
 title = {AMPD2 regulates GTP synthesis and is mutated in a potentially treatable neurodegenerative brainstem disorder},
 type = {article},
 year = {2013},
 identifiers = {[object Object]},
 volume = {154},
 id = {c3863fad-1291-334a-9e2f-f4a5f39ff30b},
 created = {2016-12-13T09:46:58.000Z},
 file_attached = {false},
 profile_id = {a7a6bb82-ebe5-31d9-85c5-e67e479a1776},
 group_id = {a84e3e74-b76a-3098-bae1-c8a78c436569},
 last_modified = {2017-03-14T14:02:54.442Z},
 read = {false},
 starred = {false},
 authored = {false},
 confirmed = {false},
 hidden = {false},
 private_publication = {false},
 abstract = {Purine biosynthesis and metabolism, conserved in all living organisms, is essential for cellular energy homeostasis and nucleic acid synthesis. The de novo synthesis of purine precursors is under tight negative feedback regulation mediated by adenosine and guanine nucleotides. We describe a distinct early-onset neurodegenerative condition resulting from mutations in the adenosine monophosphate deaminase 2 gene (AMPD2). Patients have characteristic brain imaging features of pontocerebellar hypoplasia (PCH) due to loss of brainstem and cerebellar parenchyma. We found that AMPD2 plays an evolutionary conserved role in the maintenance of cellular guanine nucleotide pools by regulating the feedback inhibition of adenosine derivatives on de novo purine synthesis. AMPD2 deficiency results in defective GTP-dependent initiation of protein translation, which can be rescued by administration of purine precursors. These data suggest AMPD2-related PCH as a potentially treatable early-onset neurodegenerative disease. © 2013 Elsevier Inc.},
 bibtype = {article},
 author = {Akizu, N. and Cantagrel, V. and Schroth, J. and Cai, N. and Vaux, K. and McCloskey, D. and Naviaux, R.K. and Van Vleet, J. and Fenstermaker, A.G. and Silhavy, J.L. and Scheliga, J.S. and Toyama, K. and Morisaki, H. and Sonmez, F.M. and Celep, F. and Oraby, A. and Zaki, M.S. and Al-Baradie, R. and Faqeih, E.A. and Saleh, M.A.M. and Spencer, E. and Rosti, R.O. and Scott, E. and Nickerson, E. and Gabriel, S. and Morisaki, T. and Holmes, E.W. and Gleeson, J.G.},
 journal = {Cell},
 number = {3}
}

Downloads: 0